COMMENTARY: Saving Noah’s Ark – The Endangered Species Act

At a recent hearing on Capitol Hill on the Endangered Species Act, it was clear that some legislators in the room were either not familiar with the story of Noah’s Ark or didn’t see its wisdom. The authors and signers of the Endangered Species Act created legislation that serves as a modern day ark to […]

COMMENTARY: Biopharmaceuticals healing Delaware

Nearly 22,000 women will be diagnosed with ovarian cancer this year. Another 14,000 will die from the disease.

One Delaware biotech firm is working to change that. In December, Wilmington-based AstraZeneca Pharmaceuticals released Lynparza, a new medicine for women with advanced ovarian cancer.

Innovative treatments like Lynparza help Delaware patients live longer and healthier lives. Drug development also keeps Delaware’s economy healthy by creating jobs and supporting local businesses. But now, Congress may jeopardize the health of our state and its residents with ill-advised changes to Medicare Part D and patent laws. Our representatives in Washington must reject such moves.